Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Holdings America, Inc. (MTHA) plans to establish a new...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S....
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a global clinical study exploring daily dosing of an investigational...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Soleo Health today announced a virtual poster presentation reviewing the analysis of real-world...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three amyotrophic lateral sclerosis (ALS) presentations as part of the Motor Neurone...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced results from a post-hoc analysis that examined the use of clinical staging systems to...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that patient enrollment has been completed for the global Phase 3 open-label study...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Aleia Kristene Asbey, aspiring screenwriter and participant in the ALSO US™...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a poster presentation of a Phase 3 edaravone study post-hoc analysis assessing...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the global Phase 3 study to evaluate the long-term safety and tolerability of an...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced updates related to the company's commitment to the amyotrophic lateral sclerosis (ALS)...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) has initiated a Phase-3...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the launch of RADICAVA® (edaravone) JourneyMate™, a new program connecting people with...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today reported that more than 5,000 people with amyotrophic lateral sclerosis (ALS) have received the...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced the presentation today of a new post-hoc analysis assessing its Phase 3 edaravone study...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of a new analysis examining real-world clinical outcomes of treatment...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced six presentations on amyotrophic lateral sclerosis (ALS), including new results...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a global Phase 3 study evaluating the long-term safety and...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.